Patents Assigned to Bioinvent International AB
  • Patent number: 10351970
    Abstract: The present invention relates to screening methods and, in particular, to methods of screening anti-ligand libraries for identifying anti-ligands specific for differentially and/or infrequently expressed ligands. The method comprises the steps of providing a library of anti-ligands: providing a first subtractor ligand; providing a second target ligand; determining the amount of the first and second target ligands using one or more equations derived from the universal law of mass action; providing the determined amount of a first subtractor ligand; providing the determined amount of a second target ligand; providing separation means capable of use to isolate anti-ligand bound to the second target ligand from anti-ligand bound to the first subtractor ligand; exposing the library of to the first and second target ligands to permit binding of anti-ligands to ligands; and using the separation means to isolate the anti-ligand bound to second target ligand.
    Type: Grant
    Filed: February 29, 2016
    Date of Patent: July 16, 2019
    Assignee: BioInvent International AB
    Inventor: Björn Frendéus
  • Patent number: 10191049
    Abstract: The present invention relates to improved screening methods and, in particular, to methods of screening anti-ligand libraries for identifying anti-ligands specific for differentially and/or infrequently expressed ligands.
    Type: Grant
    Filed: September 20, 2012
    Date of Patent: January 29, 2019
    Assignee: BioInvent International AB
    Inventors: Bjorn Frendeus, Jenny Mattsson
  • Publication number: 20180221482
    Abstract: There is provided antibodies or antigen-binding fragments thereof with binding specificity for ICAM-1, together with further anti-cancer agents, and compositions thereof, for use in the treatment of cancer.
    Type: Application
    Filed: December 19, 2017
    Publication date: August 9, 2018
    Applicant: BioInvent International AB
    Inventors: Björn Frendéus, Markus Hansson
  • Patent number: 9803013
    Abstract: The invention provides binding molecules, including antibody molecules which selectively bind to a cell surface antigen of a target cell, and wherein the binding molecules, on binding the cell surface antigen, induce cell death of the target cell. There is also provided methods of and pharmaceutical compositions for cell death induction and uses thereof.
    Type: Grant
    Filed: April 11, 2014
    Date of Patent: October 31, 2017
    Assignee: BioInvent International AB
    Inventors: Björn Frendéus, Roland Carlsson, Ingrid Teige, Linda Mårtensson
  • Publication number: 20170107293
    Abstract: Description of a composition comprising an antibody molecule and an agent for use in the treatment of refractory cancer and/or relapsed cancer, and of a method of treating refractory cancer and/or relapsed cancer comprising administering an antibody molecule and an agent. There are also described kits comprising the antibody molecule and agents.
    Type: Application
    Filed: May 15, 2015
    Publication date: April 20, 2017
    Applicant: BIOINVENT INTERNATIONAL AB
    Inventors: Björn Frendéus, Ingrid Teige, Linda Mårtensson, Mark Cragg, Ali Roghanian
  • Publication number: 20160312383
    Abstract: The present invention relates to screening methods and, in particular, to methods of screening anti-ligand libraries for identifying anti-ligands specific for differentially and/or infrequently expressed ligands. The method comprises the steps of providing a library of anti-ligands; providing a first subtractor ligand; providing a second target ligand; determining the amount of the first and second target ligands using one or more equations derived from the universal law of mass action; providing the determined amount of a first subtractor ligand; providing the determined amount of a second target ligand: providing separation means capable of use to isolate anti-ligand bound to the second target ligand from anti-ligand bound to the first subtractor ligand; exposing the library of to the first and second target ligands to permit binding of anti-ligands to ligands; and using the separation means to isolate the anti-ligand bound to second target ligand.
    Type: Application
    Filed: February 29, 2016
    Publication date: October 27, 2016
    Applicant: BioInvent International AB
    Inventor: Björn Frendéus
  • Publication number: 20160280788
    Abstract: There is provided antibodies or antigen-binding fragments thereof with binding specificity for ICAM-1, for use in the treatment of cancer in patients who have previously been treated for cancer and either not responded to said treatment or have previously responded to said treatment and subsequently relapsed.
    Type: Application
    Filed: January 27, 2016
    Publication date: September 29, 2016
    Applicant: BioInvent International AB
    Inventors: Markus Hansson, Björn Frendéus
  • Publication number: 20140314793
    Abstract: The invention provides binding molecules, including antibody molecules which selectively bind to a cell surface antigen of a target cell, and wherein the binding molecules, on binding the cell surface antigen, induce cell death of the target cell. There is also provided methods of and pharmaceutical compositions for cell death induction and uses thereof.
    Type: Application
    Filed: April 11, 2014
    Publication date: October 23, 2014
    Applicant: BIOINVENT INTERNATIONAL AB
    Inventors: Björn Frendéus, Roland Carlsson, Ingrid Teige, Linda Mårtensson
  • Publication number: 20140242072
    Abstract: The invention relates to the use of an antibody or an antigen-binding fragment thereof with binding specificity for ICAM-1, or a variant, fusion or derivative of said antibody or an antigen-binding fragment with binding specificity for ICAM-1, for the treatment of a multiple-myeloma-related disorder. The invention also relates to methods for the administration of such antibodies, fragments, variants, fusion and derivatives thereof.
    Type: Application
    Filed: September 27, 2012
    Publication date: August 28, 2014
    Applicant: BIOINVENT INTERNATIONAL AB
    Inventor: Markus Hansson
  • Publication number: 20140227249
    Abstract: The present invention relates to improved screening methods and, in particular, to methods of screening anti-ligand libraries for identifying anti-ligands specific for differentially and/or infrequently expressed ligands.
    Type: Application
    Filed: September 20, 2012
    Publication date: August 14, 2014
    Applicant: BIOINVENT INTERNATIONAL AB
    Inventors: Bjorn Frendeus, Jenny Mattsson
  • Publication number: 20140200152
    Abstract: The present invention relates to screening methods and, in particular, to methods of screening anti-ligand libraries for identifying anti-ligands specific for differentially and/or infrequently expressed ligands. The method comprises the steps of providing a library of anti-ligands; providing a first subtractor ligand; providing a second target ligand; determining the amount of the first and second target ligands using one or more equations derived from the universal law of mass action; providing the determined amount of a first subtractor ligand; providing the determined amount of a second target ligand; providing separation means capable of use to isolate anti-ligand bound to the second target ligand from anti-ligand bound to the first subtractor ligand; exposing the library of to the first and second target ligands to permit binding of anti-ligands to ligands; and using the separation means to isolate the anti-ligand bound to second target ligand.
    Type: Application
    Filed: October 15, 2013
    Publication date: July 17, 2014
    Applicant: BIOINVENT INTERNATIONAL AB
    Inventor: Björn Frendéus
  • Patent number: 8758749
    Abstract: The invention provides binding molecules, including antibody molecules which selectively bind to a cell surface antigen of a target cell, and wherein the binding molecules, on binding the cell surface antigen, induce apoptosis of the target cell. There is also provided methods of and pharmaceutical compositions for apoptosis induction and uses thereof.
    Type: Grant
    Filed: March 22, 2011
    Date of Patent: June 24, 2014
    Assignee: BioInvent International AB
    Inventors: Bjorn Frendéus, Anne-Christine Carlsson
  • Publication number: 20120077710
    Abstract: The present invention relates to a method for in vivo molecular evolution of antibody function. According to the present invention, a nucleic acid encoding a CDR that is normally contained in a framework (the “original framework”), which differs from a selected master framework, is amplified from an immunoglobulin gene and is inserted into a nucleic acid encoding the selected master framework. The invention further provides an antibody library, such as a phage display library, and methods of making the same.
    Type: Application
    Filed: May 16, 2011
    Publication date: March 29, 2012
    Applicant: BIOINVENT INTERNATIONAL AB
    Inventors: Mats Ohlin, Eskil Soderlind, Roland Carlsson
  • Patent number: 7943744
    Abstract: The invention provides binding molecules, including antibody molecules which selectively bind to a cell surface antigen of a target cell, and wherein the binding molecules, on binding the cell surface antigen, induce apoptosis of the target cell. There is also provided methods of and pharmaceutical compositions for apoptosis induction and uses thereof.
    Type: Grant
    Filed: December 8, 2006
    Date of Patent: May 17, 2011
    Assignee: BioInvent International AB
    Inventors: Björn Frendéus, Roland Carlsson, Anne-Christine Carlsson, legal representative
  • Publication number: 20100119526
    Abstract: DLL4-binding antibodies, specifically antibodies preventing Notch signaling and internalization of DLL4, can: more efficiently than inhibitors only preventing DLL4-mediated Notch-signaling disrupt angiogenesis and pathological processes including tumor growth.
    Type: Application
    Filed: January 28, 2008
    Publication date: May 13, 2010
    Applicant: BIOINVENT INTERNATIONAL AB
    Inventor: Mats Hellström
  • Publication number: 20090208503
    Abstract: The use of immunotherapy against oxidised LDL to induce regression of pre-existing atherosclerotic lesions in an individual. The immunotherapy can be passive immunotherapy utilising antibodies that bind to epitopes present on oxidised LDL, or active immunotherapy utilising a vaccine composition for induction of an immune response against epitopes present on oxidised LDL.
    Type: Application
    Filed: September 4, 2006
    Publication date: August 20, 2009
    Applicant: BIOINVENT INTERNATIONAL AB
    Inventors: Roland Carlsson, Anne-Christine Carlsson, Jan Nilsson
  • Patent number: 7521046
    Abstract: The present invention relates to passive immunization for treating or preventing atherosclerosis using an isolated human antibody directed towards at least one oxidized fragment of apolipoprotein B in the manufacture of a pharmaceutical composition for therapeutical or prophylactical treatment of atherosclerosis by means of passive immunization, as well as method for preparing such antibodies, and a method for treating a mammal, preferably a human using such an antibody to provide for passive immunization.
    Type: Grant
    Filed: October 30, 2007
    Date of Patent: April 21, 2009
    Assignee: BIOINVENT International AB
    Inventors: Jan Nilsson, Roland Carlsson, Jenny Bengtsson, Leif Strandberg
  • Publication number: 20090060915
    Abstract: The present invention relates to prophylactic or therapeutic treatments for hindering blood vessel formation (for example, angiogenesis) for example for hindering tumour growth. In particular, the invention relates to a vaccine or medicament comprising a whole angiomotin molecule or a fragment thereof which may be used to generate immune responses to angiomotin. The invention also provides antibodies specific for a whole angiomotin molecule or a fragment thereof for use in prophylactic or therapeutic treatments.
    Type: Application
    Filed: April 28, 2006
    Publication date: March 5, 2009
    Applicant: BIOINVENT INTERNATIONAL AB
    Inventor: Lars Holmgren
  • Patent number: 7432083
    Abstract: The present invention relates to a method for in vitro creation of molecular libraries evolution of protein function. Particularly, it relates to variability and modification of protein function by shuffling polynucleotide sequence segments. A protein of desired characteristics can be obtained by incorporating variant peptide regions (variant motifs) into defined peptide regions (scaffold sequence). The variant motifs can be obtained from parent DNA which has been subjected to mutagenesis to create a plurality of differently mutated derivatives thereof or they can be obtained from in vivo sequences. These variant motifs can then be incorporated into a scaffold sequence and the resulting coded protein screened for desired characteristics. This method is ideally used for obtaining antibodies with desired characteristics by isolating individual CDR DNA sequences and incorporating them into a scaffold which may, for example, be from a totally different antibody.
    Type: Grant
    Filed: April 19, 2005
    Date of Patent: October 7, 2008
    Assignee: Bioinvent International AB
    Inventors: Ulf Hans Eskil Soderlind, Carl Arne Krister Borrebaeck
  • Publication number: 20080075716
    Abstract: The present invention relates to passive immunization for treating or preventing atherosclerosis using an isolated human antibody directed towards at least one oxidized fragment of apolipoprotein B in the manufacture of a pharmaceutical composition for therapeutical or prophylactical treatment of atherosclerosis by means of passive immunization, as well as method for preparing such antibodies, and a method for treating a mammal, preferably a human using such an antibody to provide for passive immunization.
    Type: Application
    Filed: October 30, 2007
    Publication date: March 27, 2008
    Applicant: BIOINVENT INTERNATIONAL AB
    Inventors: Jan Nilsson, Roland Carlsson, Jenny Bengtsson, Leif Strandberg